Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Nanotheranostics is Scopus-indexed (Q1, CiteScore 16.3), DOAJ. Published by Ivyspring International Publisher.
Checked against the index lists dated .
ISSN 2206-7418Verify ISSN ↗
Publisher: Ivyspring International Publisher
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | 1 / 57 | 99th | Q1 |
| Medicine (miscellaneous) | 17 / 466 | 96th | Q1 |
| Biotechnology | 21 / 325 | 93rd | Q1 |
| Biomedical Engineering | 25 / 342 | 92nd | Q1 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2017–present, best quartile Q1, CiteScore 16.3.
Nanotheranostics is Q1 in Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (rank 1 of 57), Q1 in Medicine (miscellaneous) (rank 17 of 466) and Q1 in Biotechnology (rank 21 of 325), by CiteScore 2025. It is ranked in 4 subject areas in all.
Nanotheranostics is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 16.3, quartile Q1, 99th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.107, quartile Q1, with an H-index of 43.
The publisher lists an article processing charge of about US$668 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Nanotheranostics is published by Ivyspring International Publisher. Its ISSN is 2206-7418.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Nanotheranostics has an h-index of 50 and a 2-year mean of 6.61 citations per paper (OpenAlex). Its Scopus CiteScore is 16.3, quartile Q1. On 2-year citations it ranks #2 of 52 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (miscellaneous).
Nanotheranostics published 33 papers in 2025; its busiest recent year was 2021 with 47. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2022–2026), authors are most often from India (37%), United States (21.9%) and Indonesia (5.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.